Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 13-Mar-18 6:09 PM View:  | Sonsini Peter W. 10% Owner | Oncothyreon Inc (CASC) | 09-Mar-18 | Disposition (change in control) Duplicate | 10,882,600 | -- | -- | (100%) 10.88M to 0 | |
| 13-Mar-18 6:08 PM View: | Mott David M 10% Owner | Oncothyreon Inc (CASC) | 09-Mar-18 | Disposition (change in control) Duplicate | 10,882,600 | -- | -- | (100%) 10.88M to 0 | |
| 13-Mar-18 6:07 PM View: | Spiegelman Daniel K Director | Oncothyreon Inc (CASC) | 09-Mar-18 | Disposition (change in control) | 21,006 | -- | -- | (100%) 21.01K to 0 | |
| 13-Mar-18 6:02 PM View: | Christianson Gary Chief Operating Officer | Oncothyreon Inc (CASC) | 09-Mar-18 | Disposition (change in control) | 6,515 | -- | -- | (100%) 6.51K to 0 | |
| 13-Mar-18 6:07 PM View: | Myers Scott Dunseth President and CEO Director | Oncothyreon Inc (CASC) | 09-Mar-18 | Disposition (change in control) | 56,787 | -- | -- | (100%) 56.79K to 0 | |
| 13-Mar-18 6:06 PM View: | Barris Peter J 10% Owner | Oncothyreon Inc (CASC) | 09-Mar-18 | Disposition (change in control) Duplicate | 10,882,600 | -- | -- | (100%) 10.88M to 0 | |
| 13-Mar-18 6:09 PM View: | Sandell Scott D 10% Owner | Oncothyreon Inc (CASC) | 09-Mar-18 | Disposition (change in control) Duplicate | 10,882,600 | -- | -- | (100%) 10.88M to 0 | |
| 13-Mar-18 6:07 PM View: | Peterson Scott Robert Chief Scientific Officer | Oncothyreon Inc (CASC) | 09-Mar-18 | Disposition (change in control) | 3,639 | -- | -- | (100%) 3.64K to 0 | |
| 13-Mar-18 6:11 PM View: | James Steven P Director | Oncothyreon Inc (CASC) | 09-Mar-18 | Disposition (change in control) | 13,677 | -- | -- | (100%) 13.68K to 0 | |
| 13-Mar-18 6:08 PM View: | Sakoda Jon 10% Owner | Oncothyreon Inc (CASC) | 09-Mar-18 | Disposition (change in control) Duplicate | 10,882,600 | -- | -- | (100%) 10.88M to 0 | |
| 13-Mar-18 6:01 PM View: | Henney Christopher S Director | Oncothyreon Inc (CASC) | 09-Mar-18 | Disposition (change in control) | 60,185 | -- | -- | (100%) 60.19K to 0 | |
| 13-Mar-18 6:15 PM View: | Walker Luke Nathaniel SVP, Clinical Development | Oncothyreon Inc (CASC) | 09-Mar-18 | Disposition (change in control) | 10,315 | -- | -- | (100%) 10.31K to 0 | |
| 13-Mar-18 6:06 PM View: | Growth Equity Opportunities... 10% Owner | Oncothyreon Inc (CASC) | 09-Mar-18 | Disposition (change in control) | 10,882,600 | -- | -- | (100%) 10.88M to 0 | |
| 13-Mar-18 6:01 PM View: | Eastland Julia Marie CFO & CBO | Oncothyreon Inc (CASC) | 09-Mar-18 | Disposition (change in control) | 5,237 | -- | -- | (100%) 5.24K to 0 | |
| 13-Mar-18 6:07 PM View: | Florence Anthony A. Jr. 10% Owner | Oncothyreon Inc (CASC) | 09-Mar-18 | Disposition (change in control) Duplicate | 10,882,600 | -- | -- | (100%) 10.88M to 0 | |
| 13-Mar-18 6:10 PM View: | Viswanathan Ravi 10% Owner | Oncothyreon Inc (CASC) | 09-Mar-18 | Disposition (change in control) Duplicate | 10,882,600 | -- | -- | (100%) 10.88M to 0 | |
| 13-Mar-18 6:11 PM View: | Fyfe Gwen A. Director | Oncothyreon Inc (CASC) | 09-Mar-18 | Disposition (change in control) | 10,125 | -- | -- | (100%) 10.13K to 0 | |
| 13-Mar-18 6:07 PM View: | Makower Joshua 10% Owner | Oncothyreon Inc (CASC) | 09-Mar-18 | Disposition (change in control) Duplicate | 10,882,600 | -- | -- | (100%) 10.88M to 0 | |
| 13-Mar-18 6:11 PM View: | Love Ted W Director | Oncothyreon Inc (CASC) | 09-Mar-18 | Disposition (change in control) | 37,394 | -- | -- | (100%) 37.39K to 0 | |
| 13-Mar-18 6:07 PM View: | Baskett Forest 10% Owner | Oncothyreon Inc (CASC) | 09-Mar-18 | Disposition (change in control) Duplicate | 10,882,600 | -- | -- | (100%) 10.88M to 0 | |
| 22-Feb-18 4:44 PM View: | Sandell Scott D 10% Owner | Oncothyreon Inc (CASC) | 20-Feb-18 | Conversion Duplicate | 1,818,000 | $3.30 | $5,999,400.00 | 20% 9.06M to 10.88M | |
| 22-Feb-18 4:44 PM View: | Sakoda Jon 10% Owner | Oncothyreon Inc (CASC) | 20-Feb-18 | Conversion Duplicate | 1,818,000 | $3.30 | $5,999,400.00 | 20% 9.06M to 10.88M | |
| 22-Feb-18 4:41 PM View: | Growth Equity Opportunities... 10% Owner | Oncothyreon Inc (CASC) | 20-Feb-18 | Conversion | 1,818,000 | $3.30 | $5,999,400.00 | 20% 9.06M to 10.88M | |
| 22-Feb-18 4:43 PM View: | Florence Anthony A. Jr. 10% Owner | Oncothyreon Inc (CASC) | 20-Feb-18 | Conversion Duplicate | 1,818,000 | $3.30 | $5,999,400.00 | 20% 9.06M to 10.88M | |
| 22-Feb-18 4:45 PM View: | Viswanathan Ravi 10% Owner | Oncothyreon Inc (CASC) | 20-Feb-18 | Conversion Duplicate | 1,818,000 | $3.30 | $5,999,400.00 | 20% 9.06M to 10.88M | |
| 22-Feb-18 4:43 PM View: | Makower Joshua 10% Owner | Oncothyreon Inc (CASC) | 20-Feb-18 | Conversion Duplicate | 1,818,000 | $3.30 | $5,999,400.00 | 20% 9.06M to 10.88M | |
| 22-Feb-18 4:42 PM View: | Baskett Forest 10% Owner | Oncothyreon Inc (CASC) | 20-Feb-18 | Conversion Duplicate | 1,818,000 | $3.30 | $5,999,400.00 | 20% 9.06M to 10.88M | |
| 22-Feb-18 4:45 PM View: | Sonsini Peter W. 10% Owner | Oncothyreon Inc (CASC) | 20-Feb-18 | Conversion Duplicate | 1,818,000 | $3.30 | $5,999,400.00 | 20% 9.06M to 10.88M | |
| 22-Feb-18 4:44 PM View: | Mott David M 10% Owner | Oncothyreon Inc (CASC) | 20-Feb-18 | Conversion Duplicate | 1,818,000 | $3.30 | $5,999,400.00 | 20% 9.06M to 10.88M | |
| 22-Feb-18 4:42 PM View: | Barris Peter J 10% Owner | Oncothyreon Inc (CASC) | 20-Feb-18 | Conversion Duplicate | 1,818,000 | $3.30 | $5,999,400.00 | 20% 9.06M to 10.88M | |
| 16-Jan-18 5:28 PM View: | Peterson Scott Robert Chief Scientific Officer | Oncothyreon Inc (CASC) | 11-Jan-18 | Option Exercise | 2,825 | -- | -- | 163% 1.74K to 4.56K | |
| 16-Jan-18 5:26 PM View: | Myers Scott Dunseth President and CEO Director | Oncothyreon Inc (CASC) | 11-Jan-18 | Payment of Exercise | 3,429 | $3.92 | $13,441.70 | (6%) 60.22K to 56.79K | |
| 16-Jan-18 5:29 PM View: | Walker Luke Nathaniel SVP, Clinical Development | Oncothyreon Inc (CASC) | 11-Jan-18 | Option Exercise | 1,950 | -- | -- | 49% 3.99K to 5.94K | |
| 16-Jan-18 5:25 PM View: | Eastland Julia Marie CFO & CBO | Oncothyreon Inc (CASC) | 11-Jan-18 | Option Exercise | 2,825 | -- | -- | 85% 3.33K to 6.16K | |
| 16-Jan-18 5:26 PM View: | Myers Scott Dunseth President and CEO Director | Oncothyreon Inc (CASC) | 11-Jan-18 | Option Exercise | 10,500 | -- | -- | 21% 49.72K to 60.22K | |
| 16-Jan-18 5:24 PM View: | Christianson Gary Chief Operating Officer | Oncothyreon Inc (CASC) | 11-Jan-18 | Payment of Exercise | 923 | $3.92 | $3,618.16 | (12%) 7.44K to 6.51K | |
| 16-Jan-18 5:28 PM View: | Peterson Scott Robert Chief Scientific Officer | Oncothyreon Inc (CASC) | 11-Jan-18 | Payment of Exercise | 923 | $3.92 | $3,618.16 | (20%) 4.56K to 3.64K | |
| 16-Jan-18 5:24 PM View: | Christianson Gary Chief Operating Officer | Oncothyreon Inc (CASC) | 11-Jan-18 | Option Exercise | 2,825 | -- | -- | 61% 4.61K to 7.44K | |
| 16-Jan-18 5:29 PM View: | Walker Luke Nathaniel SVP, Clinical Development | Oncothyreon Inc (CASC) | 11-Jan-18 | Payment of Exercise | 637 | $3.92 | $2,497.04 | (11%) 5.94K to 5.3K | |
| 16-Jan-18 5:25 PM View: | Eastland Julia Marie CFO & CBO | Oncothyreon Inc (CASC) | 11-Jan-18 | Payment of Exercise | 923 | $3.92 | $3,618.16 | (15%) 6.16K to 5.24K | |
| 26-Sep-17 5:22 PM View: | Spiegelman Daniel K Director | Oncothyreon Inc (CASC) | 24-Sep-17 | Payment of Exercise | 594 | $3.94 | $2,340.36 | (3%) 21.6K to 21.01K | (156%) |
| 26-Sep-17 5:20 PM View: | James Steven P Director | Oncothyreon Inc (CASC) | 24-Sep-17 | Option Exercise | 2,375 | -- | -- | 20% 11.9K to 14.27K | |
| 26-Sep-17 5:21 PM View: | Love Ted W Director | Oncothyreon Inc (CASC) | 24-Sep-17 | Option Exercise | 2,375 | -- | -- | 7% 35.61K to 37.99K | |
| 26-Sep-17 5:22 PM View: | Spiegelman Daniel K Director | Oncothyreon Inc (CASC) | 24-Sep-17 | Option Exercise | 2,375 | -- | -- | 12% 19.23K to 21.6K | |
| 26-Sep-17 5:21 PM View: | Love Ted W Director | Oncothyreon Inc (CASC) | 24-Sep-17 | Payment of Exercise | 594 | $3.94 | $2,340.36 | (2%) 37.99K to 37.39K | (156%) |
| 26-Sep-17 5:20 PM View: | James Steven P Director | Oncothyreon Inc (CASC) | 24-Sep-17 | Payment of Exercise | 594 | $3.94 | $2,340.36 | (4%) 14.27K to 13.68K | (156%) |
| 26-Sep-17 5:19 PM View: | Henney Christopher S Director | Oncothyreon Inc (CASC) | 24-Sep-17 | Payment of Exercise | 594 | $3.94 | $2,340.36 | (< 1%) 60.78K to 60.19K | (156%) |
| 26-Sep-17 5:19 PM View: | Henney Christopher S Director | Oncothyreon Inc (CASC) | 24-Sep-17 | Option Exercise | 2,375 | -- | -- | 4% 58.4K to 60.78K | |
| 14-Aug-17 5:12 PM View: | Myers Scott Dunseth President and CEO Director | Oncothyreon Inc (CASC) | 11-Aug-17 | Market Purchase | 5,500 | $3.73 | $20,542.50 | 12% 44.22K to 49.72K | 170% |
| 27-Jun-17 5:41 PM View: | Spiegelman Daniel K Director | Oncothyreon Inc (CASC) | 24-Jun-17 | Option Exercise | 9,058 | -- | -- | 73% 12.43K to 21.49K |
